St. Jude Medical (STJ) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Deutsche Bank Downgrades St. Jude Medical (STJ) to Hold
July 23, 2015 7:17 AM EDTDeutsche Bank downgraded St. Jude Medical (NYSE: STJ) from Buy to Hold with a price target of $77.00 (from $76.00). The downgrade follows recent outperformance.
Analyst Kisten Stewart said, "We upgraded STJ shares to Buy in Feb 2011 after its investor day as we were impressed... More
St. Jude Medical (STJ) PT Raised to $80 at Evercore ISI on Thoratec Accretion
July 22, 2015 1:57 PM EDTEvercore ISI analyst Vijay Kumar raised estimates and his price target on St. Jude Medical (NYSE: STJ) to $80.00 (from $77.50) following the acquisition of Thoratec (NASDAQ: THOR) but maintained a Hold rating.
Kumar commented, "STJ's quarterly results took a backseat with investors mainly focused on the announcement of acquisition of Thoratec, a leading LVAD (left ventricular assist device) player for Class IV heart failure patients. Strategically the acquisition makes sense for STJ, given its... More
St. Jude Medical (STJ) to Acquire Thoratec (THOR) for $63.50/Share in Cash
July 22, 2015 7:00 AM EDT(Updated - July 22, 2015 7:01 AM EDT)
St. Jude Medical (NYSE: STJ) and Thoratec (NASDAQ: THOR) announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash transaction valued at approximately $3.4 billion, net of cash acquired. The all-cash transaction represents a premium of 40.1 percent compared to $45.34, Thoratec's volume-weighted average trading price for the 30 trading day period ending July 17, 2015, and a 35.4 percent premium to the closing price on... More
